Shouyao Holdings (Beijing) Co. Ltd. A Total Liabilities
Shouyao Holdings (Beijing) Co. Ltd. A total liabilities. Based on the latest financial reports, Shouyao Holdings (Beijing) Co. Ltd. A (688197) has total liabilities worth CN¥106.61 Million CNY (≈ $15.60 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Shouyao Holdings (Beijing) Co. Ltd. A liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shouyao Holdings (Beijing) Co. Ltd. A (2019–2025)
Total liabilities of Shouyao Holdings (Beijing) Co. Ltd. A from 2019 to 2025. This chart illustrates how Shouyao Holdings (Beijing) Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data.
Shouyao Holdings (Beijing) Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Shouyao Holdings (Beijing) Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
Taiwan | NT$5.07 Billion |
|
Ningbo Thermal Power Co Ltd
SHG:600982
|
China | CN¥11.13 Billion |
|
Rayhoo Motor Dies Co Ltd
SHE:002997
|
China | CN¥4.34 Billion |
|
China Yuchai International Limited
NYSE:CYD
|
USA | $14.75 Billion |
|
Cablevision Holding SA
BA:CVH
|
Argentina | AR$9.10 Trillion |
|
Safehold Inc
NYSE:SAFE
|
USA | $4.89 Billion |
|
Guangzhou Automobile Group Co. Ltd
F:02G
|
Germany | €115.67 Billion |
|
Zhongzhong Science & Technology (Tianjin) Co. Ltd. A
SHG:603135
|
China | CN¥868.79 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Shouyao Holdings (Beijing) Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Shouyao Holdings (Beijing) Co. Ltd. A assets under control.
Liquidity & Leverage Metrics
Shouyao Holdings (Beijing) Co. Ltd. A Total Liabilities Ratios Explained
Shouyao Holdings (Beijing) Co. Ltd. A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shouyao Holdings (Beijing) Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shouyao Holdings (Beijing) Co. Ltd. A (2019–2025)
The table below shows the annual total liabilities of Shouyao Holdings (Beijing) Co. Ltd. A from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥111.05 Million ≈ $16.25 Million |
-1.91% |
| 2024-12-31 | CN¥113.21 Million ≈ $16.57 Million |
+24.20% |
| 2023-12-31 | CN¥91.16 Million ≈ $13.34 Million |
-1.70% |
| 2022-12-31 | CN¥92.73 Million ≈ $13.57 Million |
+63.62% |
| 2021-12-31 | CN¥56.67 Million ≈ $8.29 Million |
+58.70% |
| 2020-12-31 | CN¥35.71 Million ≈ $5.23 Million |
-19.44% |
| 2019-12-31 | CN¥44.33 Million ≈ $6.49 Million |
-- |
About Shouyao Holdings (Beijing) Co. Ltd. A
Shouyao Holdings (Beijing) Co., LTD. engages in the research, development, and production of drugs in China. The company offers drugs for oncology indications, including non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, breast cancer, ovarian cancer, thyroid cancer, leukemia, and diabetes. The company was founded in 2016 and is headquartered in Beijing, China.